---
title: "SUNFLOWER plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical. Stock resumption"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258217571.md"
description: "SUNFLOWER plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical through the issuance of shares and cash payment, and to raise supporting funds. Xipu Materials focuses on the research and development and sales of high-end semiconductor materials, while Beid Pharmaceutical is a holding subsidiary mainly engaged in drug research and manufacturing. This transaction will enhance the company's asset quality, promote long-term development, and enter the high-end semiconductor materials field, adding new profit growth points. The company's stock will resume trading on September 22, 2025"
datetime: "2025-09-21T08:24:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258217571.md)
  - [en](https://longbridge.com/en/news/258217571.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258217571.md)
---

# SUNFLOWER plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical. Stock resumption

According to the Zhitong Finance APP, SUNFLOWER (300111.SZ) announced that the company plans to purchase 100% equity of Xipu Materials held by six trading parties including Shanghai Xipu through the issuance of shares and cash payment, and to acquire 40% equity of Beid Pharmaceutical from SUNFLOWER Investment, while raising supporting funds. The company's stock will resume trading on September 22, 2025 (Monday) at the market opening.

Xipu Materials mainly engages in the research, development, manufacturing, and sales of high-end semiconductor materials, with main products including semiconductor-grade high-purity electronic special gases, silicon-based precursors, metal-based precursors, etc., which are widely used in key processes such as diffusion, etching, and thin film deposition in semiconductor manufacturing. Beid Pharmaceutical, as a subsidiary of SUNFLOWER, mainly focuses on the research, development, manufacturing, and sales of drugs related to anti-infection, cardiovascular, and digestive systems.

This transaction is beneficial for further improving the asset quality of the listed company and promoting its long-term development. Upon completion of this transaction, the listed company will enter the high-end semiconductor materials field, create a second growth curve, accelerate the transformation towards new productive forces, and increase new profit growth points, thereby further enhancing the listed company's sustainable profitability

### Related Stocks

- [300111.CN](https://longbridge.com/en/quote/300111.CN.md)

## Related News & Research

- [Chuck Schumer Accuses Trump Of Treating Federal Budget Like A 'Personal Slush Fund'](https://longbridge.com/en/news/287022865.md)
- [Peter Schiff Says With The Defeat Of Thomas Massie, Trump Has Turned The US Into A Nation Of 'Two Democratic Parties': Republicans Exists In Name Only](https://longbridge.com/en/news/287012320.md)
- [Comey eyes new 'anti-weaponization' fund: 'I'm guessing I'll be in line'](https://longbridge.com/en/news/286948735.md)
- [FACTBOX-Here are the Democrats taking early steps in potential 2028 White House bids](https://longbridge.com/en/news/286890348.md)
- [Senate Democrats call for White House election security czar's removal](https://longbridge.com/en/news/286956776.md)